Q1 2025 Management View CEO Christopher Missling highlighted key updates on the Alzheimer's treatment, blarcamesine. He emphasized the potential of the drug to offer "a scalable treatment alternative ...
Hosted on MSN28d
FDA beats EMA to most approved new drugs in 2024The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most ... In September 2024, the FDA approved the first new schizophrenia drug in more ...
Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for Alzheimer's Disease this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback